The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

Early‐phase clinical trials using oral inhibitors of MEK, the mitogen‐activated protein kinase kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1)‐associated tumors, particularly progressive low‐grade gliomas and plexiform neurofibromas. Given this potential of MEK inh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Symptom Management and Supportive Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356675/
https://ncbi.nlm.nih.gov/pubmed/32272491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0069
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados